作者
Sibo Tian, Jeffrey M Switchenko, Zachary S Buchwald, Pretesh R Patel, Joseph W Shelton, Shannon E Kahn, Rathi N Pillai, Conor E Steuer, Taofeek K Owonikoko, Madhusmita Behera, Walter J Curran, Kristin A Higgins
发表日期
2020/1/24
期刊
International Journal of Radiation Oncology* Biology* Physics
出版商
Elsevier
简介
Purpose
Radical treatment of metastases with stereotactic body radiation therapy (SBRT) is commonly implemented in patients receiving concurrent immune checkpoint inhibition (ICI), despite limited safety and toxicity data. The purpose of this study was to evaluate the safety and tolerability of lung SBRT with concurrent ICI.
Methods and Materials
Records from a single academic institution were reviewed to identify patients treated with lung SBRT and concurrent (within 30 days) ICI; a contemporaneous cohort receiving lung SBRT alone was included for reference. Treatment-related adverse effects occurring within 30 days (acute) and 180 days (subacute) of SBRT were evaluated.
Results
Our study included 117 patients; 54 received SBRT with concurrent ICI (56 courses, 69 target lesions), and 63 received SBRT alone (68 courses, 79 lesions). Median follow-up was 9.2 months in the SBRT + ICI cohort. Among the …
学术搜索中的文章
S Tian, JM Switchenko, ZS Buchwald, PR Patel… - International Journal of Radiation Oncology* Biology …, 2020
S Tian, J Switchenko, P Patel, J Shelton, S Kahn… - Journal of Thoracic Oncology, 2019